AmoyDx and BeiGene Announce Strategic Cooperation on HER2 Companion Diagnostics
Amoy Diagnostics (300685.SZ) and BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) announced a strategic partnership in the field of companion diagnostics.
AmoyDx to participate in the ESGO 2022
AmoyDx will be in attendance at the 23rd European Congress on Gynaecological Oncology ("ESGO 2022") on October 27-30 in Berlin.
AmoyDx to attend the ESMO Congress 2022
AmoyDx will exhibit at the ESMO Congress 2022 from September 9-13, 2022 in Paris, France.
AmoyDx participates in the ECP 2022
AmoyDx is happy to have attended and exhibited at the 34th European Congress of Pathology (ECP 2022) held from 3 to 7 September 2022 at the Congress Centre in the middle of the city of Basel, Switzerland.
Investigators Present Significant Research During WCLC 2022
Several key researches supported by Amoy Diagnostics were presented at WCLC 2022. The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from mor
AmoyDx® Master Panel--Study Reveals Clinically Relevant Intertumoral Heterogeneity of NSCLCs Driven by MET Exon 14 Skipping Mutation
Vienna – Aug. 7th, 2022. – A study presented at the IASLC World Conference on Lung Cancer 2022 in Vienna disclosed the clinically relevant intertumoral heterogeneity of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping (METex14 skipping).
* Required information
Manage your account info
Change your password